AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
ArriVent BioPharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$17.94+1.28 (+7.68%)
Close on Oct 19, 2026
- Market cap
- $854.07M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
93.5%
46M of 49M shares
Institutional holders
158
36 new, 15 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $12.98M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Infinitum Partners GP, LLC | 4,123,923 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Hillhouse Investment Management, Ltd. | 3,929,117 | 9.50% | 13G (passive) amendment | Dec 31, 2025 |
| Infinitum Cayman Master, Ltd. (Fund) | 3,418,923 | 9.90% | 13G (passive) | May 1, 2025 |
| Aaron Cowen | 3,412,788 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| FMR LLC | 3,407,549 | 8.40% | 13G (passive) amendment | Sep 30, 2025 |
| BlackRock, Inc. | 3,182,080 | 6.80% | 13G (passive) amendment | Jun 30, 2026 |
| Abigail P. Johnson | 3,016,132 | 6.80% | 13G (passive) amendment | Mar 31, 2026 |
| Orbimed Advisors LLC | 2,875,962 | 5.80% | 13D (active) amendment | Oct 6, 2026 |
| Vivo Opportunity, LLC | 2,472,701 | 5.00% | 13G (passive) | Oct 6, 2026 |
| HBM Healthcare Investments (Cayman) Ltd. | 2,195,014 | 5.40% | 13G (passive) | Oct 8, 2025 |
| Infinitum Asset Management, LLC | 2,066,238 | 6.10% | 13G (passive) | May 1, 2025 |
| Yi Shi | 2,046,123 | 6.40% | 13G (passive) | Jan 26, 2024 |
| Sofinnova Management XI, L.P. (“SM XI LP”) | 1,696,752 | 5.10% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AVBP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 4,515,531 | 9.16% | $156.87M | +114,448 | 2.87% |
| Infinitum Asset Management, LLC | 4,438,384 | 9.00% | $154.19M | +289,461 | 15.68% |
| Hhlr Advisors, Ltd. | 3,929,117 | 7.97% | $136.50M | – | 16.40% |
| BlackRock, Inc. | 3,250,396 | 6.59% | $112.92M | +720,095 | 0.00% |
| Orbimed Advisors LLC | 3,027,328 | 6.14% | $105.17M | – | 1.95% |
| FMR LLC | 2,778,959 | 5.64% | $96.54M | −237,173 | 0.00% |
| Octagon Capital Advisors LP | 1,971,054 | 4.00% | $68.47M | – | 6.15% |
| Vanguard Capital Management LLC | 1,774,873 | 3.60% | $61.66M | +245,980 | 0.00% |
| Sofinnova Investments, Inc. | 1,696,752 | 3.44% | $58.95M | – | 3.05% |
| State Street Corp | 1,692,986 | 3.43% | $58.81M | +271,571 | 0.00% |
| Vivo Capital, LLC | 1,682,097 | 3.41% | $58.44M | +796,181 | 5.34% |
| Novo Holdings A/S | 1,500,000 | 3.04% | $52.11M | −442,142 | 3.03% |
| General Catalyst Group Management, LLC | 1,494,786 | 3.03% | $51.93M | – | 27.55% |
| Logos Global Management LP | 1,000,000 | 2.03% | $34.74M | +650,000 | 1.50% |
| Geode Capital Management, LLC | 972,626 | 1.97% | $33.80M | +168,974 | 0.00% |
| D. E. Shaw & Co., Inc. | 872,011 | 1.77% | $30.29M | +503,216 | 0.01% |
| Goldman Sachs Group Inc | 853,723 | 1.73% | $29.66M | +296 | 0.00% |
| HSG Holding Ltd | 663,308 | 1.35% | $23.04M | – | 1.85% |
| Point72 Asset Management, L.P. | 566,796 | 1.15% | $19.69M | −181,399 | 0.02% |
| Millennium Management LLC | 438,664 | 0.89% | $15.24M | +12,741 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 158 | 46M | 93.5% | 36 / 72 | 30 / 15 | 6M | 2M |
| Q1 2026 | 139 | 42M | 85.4% | 35 / 58 | 28 / 17 | 7M | 3M |
| Q4 2025 | 122 | 40M | 81.3% | 30 / 41 | 35 / 14 | 5M | 3M |
| Q3 2025 | 106 | 39M | 78.3% | 18 / 47 | 18 / 11 | 6M | 1M |
| Q2 2025 | 99 | 34M | 68.2% | 26 / 25 | 30 / 9 | 5M | 1M |
| Q1 2025 | 83 | 29M | 59.0% | 15 / 29 | 22 / 11 | 2M | 1M |
| Q4 2024 | 80 | 28M | 57.7% | 24 / 33 | 12 / 11 | 3M | 1M |
| Q3 2024 | 68 | 26M | 52.6% | 17 / 37 | 3 / 2 | 5M | 0M |
| Q2 2024 | 54 | 22M | 43.9% | 12 / 22 | 8 / 11 | 1M | 2M |
| Q1 2024 | 53 | 22M | 44.4% | 53 / 0 | 0 / 0 | 22M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of AVBP | Value | % of fund | As of |
|---|---|---|---|---|---|
| Select Biotechnology Portfolio | 1,439,803 | 2.92% | $43.58M | 0.83% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,338,764 | 2.72% | $46.51M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 984,786 | 2.00% | $34.21M | 0.04% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 880,426 | 1.79% | $30.59M | 0.28% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 414,872 | 0.84% | $12.37M | 0.04% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 397,078 | 0.81% | $13.79M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 350,006 | 0.71% | $12.16M | 0.08% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 324,040 | 0.66% | $9.81M | 0.01% | May 31, 2026 |
| Fidelity Small Cap Growth Fund | 298,740 | 0.61% | $8.91M | 0.10% | Jul 31, 2026 |
| iShares Biotechnology ETF | 230,487 | 0.47% | $8.01M | 0.09% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 165,782 | 0.34% | $5.02M | 0.03% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 158,190 | 0.32% | $4.79M | 0.01% | May 31, 2026 |
| Fidelity Small Cap Growth K6 Fund | 149,030 | 0.30% | $4.44M | 0.10% | Jul 31, 2026 |
| Schwab U.S. Small-Cap ETF | 147,128 | 0.30% | $4.45M | 0.02% | May 31, 2026 |
| iShares Micro-Cap ETF | 127,000 | 0.26% | $4.41M | 0.29% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Stuart Lutzker | President of R&D, Director | 147,744 | 0.30% | Feb 4, 2026 |
| Zhengbin Yao | President and CEO, Director | 613,138 | 1.24% | Feb 4, 2026 |
| Robin LaChapelle | Chief Operating Officer | 523,710 | 1.06% | Feb 4, 2026 |
| Winston Kung | Chief Financial Officer | – | – | Feb 4, 2026 |
| James Paul Kastenmayer | General Counsel | 7,386 | 0.01% | Feb 4, 2026 |
| Kristine Peterson | Director | – | – | Jun 22, 2026 |
| Chris Nolet | Director | – | – | Jun 22, 2026 |
| John Hohneker | Director | – | – | Jun 22, 2026 |
| Merdad Parsey | Director | – | – | Jun 22, 2026 |
| Hhlr Advisors, Ltd. | 10% owner | 3,929,117 | 7.97% | Feb 3, 2026 |
| Hillhouse Investment Management, Ltd. | 10% owner | – | – | Feb 3, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Hhlr Advisors, Ltd. 10% owner | Dec 10, 2025 | Sale | −555,555 | $23.37 | $12.98M | 3,929,117 |
| Robin LaChapelle Chief Operating Officer | Jul 11, 2025 | Option exercise | +2,600 | $2.28 | $5.93K | 129,233 |
| Robin LaChapelle Chief Operating Officer | Jul 11, 2025 | Option exercise | +6,503 | $2.28 | $14.83K | 135,736 |
| Robin LaChapelle Chief Operating Officer | Jul 11, 2025 | Option exercise | +2,050 | $2.28 | $4.67K | 126,633 |
| Robin LaChapelle Chief Operating Officer | Sep 19, 2024 | Option exercise | +2,867 | $2.28 | $6.54K | 102,584 |
| Robin LaChapelle Chief Operating Officer | Sep 19, 2024 | Option exercise | +2,700 | $6.24 | $16.85K | 99,717 |
| Robin LaChapelle Chief Operating Officer | Sep 19, 2024 | Option exercise | +7,164 | $2.28 | $16.33K | 109,748 |
| Robin LaChapelle Chief Operating Officer | Sep 19, 2024 | Option exercise | +12,364 | $3.65 | $45.13K | 124,583 |
| Robin LaChapelle Chief Operating Officer | Sep 19, 2024 | Option exercise | +2,471 | $2.28 | $5.63K | 112,219 |
| Hhlr Advisors, Ltd. 10% owner | Jan 30, 2024 | Conversion | +3,616,041 | – | – | 3,616,041 |
| Hhlr Advisors, Ltd. 10% owner | Jan 30, 2024 | Buy | +555,555 | $18.00 | $10.00M | 4,484,672 |
| Hhlr Advisors, Ltd. 10% owner | Jan 30, 2024 | Conversion | +313,076 | – | – | 3,929,117 |
| Carl L. Gordon Director, 10% owner | Jan 30, 2024 | Buy | +222,222 | $18.00 | $4.00M | 1,513,664 |
| Carl L. Gordon Director, 10% owner | Jan 30, 2024 | Conversion | +821,827 | – | – | 821,827 |
| Carl L. Gordon Director, 10% owner | Jan 30, 2024 | Conversion | +821,827 | – | – | 821,827 |
| Carl L. Gordon Director, 10% owner | Jan 30, 2024 | Conversion | +469,615 | – | – | 1,291,442 |
| Carl L. Gordon Director, 10% owner | Jan 30, 2024 | Buy | +222,222 | $18.00 | $4.00M | 1,513,664 |
| Carl L. Gordon Director, 10% owner | Jan 30, 2024 | Conversion | +469,615 | – | – | 1,291,442 |
| OrbiMed Asia GP IV, L.P. Director, 10% owner | Jan 30, 2024 | Conversion | +821,827 | – | – | 821,827 |
| OrbiMed Asia GP IV, L.P. Director, 10% owner | Jan 30, 2024 | Conversion | +821,827 | – | – | 821,827 |
| OrbiMed Asia GP IV, L.P. Director, 10% owner | Jan 30, 2024 | Conversion | +469,615 | – | – | 1,291,442 |
| OrbiMed Asia GP IV, L.P. Director, 10% owner | Jan 30, 2024 | Conversion | +469,615 | – | – | 1,291,442 |
| OrbiMed Asia GP IV, L.P. Director, 10% owner | Jan 30, 2024 | Buy | +222,222 | $18.00 | $4.00M | 1,513,664 |
| OrbiMed Asia GP IV, L.P. Director, 10% owner | Jan 30, 2024 | Buy | +222,222 | $18.00 | $4.00M | 1,513,664 |
| James Healy Director | Jan 30, 2024 | Buy | +444,444 | $18.00 | $8.00M | 1,696,752 |
| James Healy Director | Jan 30, 2024 | Conversion | +1,252,308 | – | – | 1,252,308 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.